Abstract
The complexity of the stress response would appear to provide multiple opportunities for intervention, but treatment strategies are often centered on the improvement of symptoms rather than attempting to “treat” the stress response. However, recent efforts have begun to focus on the development of pharmacological agents that can attenuate the stress response itself, rather than the symptoms associated with stress. Although CRF, which is the main regulator of the stress system, is the focus of current interest, there is an accumulating body of evidence suggesting that the vasopressinergic system may play an equal role in the regulation of the stress response, and that V1b receptor antagonists may be of potential therapeutic benefit. The availability of SSR149415, the first selective antagonist for the V1b receptor has allowed us to evaluate this hypothesis. SSR149415 is able to attenuate some but not all stress-related behaviors in rodents. While the antidepressant-like activity of the compound was comparable to that of reference antidepressants, the overall profile displayed in anxiety tests was different from that of classical anxiolytics, such as benzodiazepines. The latter were active in a wide range of anxiety models, whereas the V1b receptor antagonist showed clear-cut effects only in particularly stressful situations. It is important to note that SSR149415 is devoid of central depressant effects, even at high doses, and does not affect cognitive processes, suggesting a large therapeutic window. Altogether, these findings suggest that V1b receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events.
Keywords: antidepressant, anxiety, anxiolytic, arginine vasopressin, depression, ssr149415, stress, receptor
Current Drug Targets - CNS & Neurological Disorders
Title: The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders
Volume: 2 Issue: 3
Author(s): Guy Griebel, Jacques Simiand, Jeanne Stemmelin, Claudine Serradeil-Le Gal and Regis Steinberg
Affiliation:
Keywords: antidepressant, anxiety, anxiolytic, arginine vasopressin, depression, ssr149415, stress, receptor
Abstract: The complexity of the stress response would appear to provide multiple opportunities for intervention, but treatment strategies are often centered on the improvement of symptoms rather than attempting to “treat” the stress response. However, recent efforts have begun to focus on the development of pharmacological agents that can attenuate the stress response itself, rather than the symptoms associated with stress. Although CRF, which is the main regulator of the stress system, is the focus of current interest, there is an accumulating body of evidence suggesting that the vasopressinergic system may play an equal role in the regulation of the stress response, and that V1b receptor antagonists may be of potential therapeutic benefit. The availability of SSR149415, the first selective antagonist for the V1b receptor has allowed us to evaluate this hypothesis. SSR149415 is able to attenuate some but not all stress-related behaviors in rodents. While the antidepressant-like activity of the compound was comparable to that of reference antidepressants, the overall profile displayed in anxiety tests was different from that of classical anxiolytics, such as benzodiazepines. The latter were active in a wide range of anxiety models, whereas the V1b receptor antagonist showed clear-cut effects only in particularly stressful situations. It is important to note that SSR149415 is devoid of central depressant effects, even at high doses, and does not affect cognitive processes, suggesting a large therapeutic window. Altogether, these findings suggest that V1b receptor antagonists might be useful as a treatment for major depression and stress disorders that result from traumatic events.
Export Options
About this article
Cite this article as:
Griebel Guy, Simiand Jacques, Stemmelin Jeanne, Gal Serradeil-Le Claudine and Steinberg Regis, The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders, Current Drug Targets - CNS & Neurological Disorders 2003; 2 (3) . https://dx.doi.org/10.2174/1568007033482850
DOI https://dx.doi.org/10.2174/1568007033482850 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Melatonin Synthetic Analogs as Nitric Oxide Synthase Inhibitors
Mini-Reviews in Medicinal Chemistry Characterization of Heme Oxygenase in Adult Rodent Platelets
Current Neurovascular Research AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Clinical Analysis Methods of Voice Disorders
Current Bioinformatics HIV-1 Tat Protein Exposure Potentiates Ethanol Reward and Reinstates Extinguished Ethanol-Conditioned Place Preference
Current HIV Research Development of Immunopharmacotherapy Against Drugs of Abuse
Current Drug Discovery Technologies Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Extend, Pathomechanism and Clinical Consequences of Brain Volume Changes in Anorexia Nervosa
Current Neuropharmacology Neurological Disorder Drug Discovery from Gene Expression with Tensor Decomposition
Current Pharmaceutical Design How to Prevent Postpartum Relapse to Smoking
Current Pediatric Reviews Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology The Clinical Neuroscience of Post Stroke Depression
Current Neuropharmacology Strategies for Autism Diagnosis and Care in Resource Deprived Settings in Africa: An Overview
Adolescent Psychiatry The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Involvement of Uridine-Nucleotide-Stimulated P2Y Receptors in Neuronal Growth and Function
Central Nervous System Agents in Medicinal Chemistry Web Service Composition Survey: State of the Art Review
Recent Patents on Computer Science The Value of Neuroimaging Techniques in the Translation and Transdiagnostic Validation of Psychiatric Diagnoses - Selective Review
Current Topics in Medicinal Chemistry